12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Vivus sales and marketing update

Vivus set the wholesale acquisition cost (WAC) for once-daily obesity drug Qsymia phentermine/topiramate at $120 per month for the lowest dose and $183.90 per month for the highest dose, according to the Red Book. The company is set to launch the drug next quarter for adults with a BMI of 30 kg/m 2 or greater, or...

Read the full 270 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >